Nasdaq
$54.17▲ 0.06%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $8.29BShares out 1.500M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
5- 9.14After-hours26.09.15 06:004Ownership#●●●
TG THERAPEUTICS, INC.
Insider Laurence N. Charney of TG THERAPEUTICS, INC. reported a change in beneficial ownership of securities effective September 10, 2026. This filing serves as a standard disclosure of insider transaction activity.…more
$54.17+0.06%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.10After-hours26.09.11 05:46144Ownership
TG THERAPEUTICS, INC.
TG Therapeutics insider Laurence N. Charney has filed an SEC Form 144 to report a proposed sale of company securities. This filing serves as a standard notification of an insider's plan to dispose of shares.…more
$54.17+0.06%vs prev closeView filingShare - 8.7After-hours26.08.08 06:004Ownership
TG THERAPEUTICS, INC.
TG THERAPEUTICS의 이사인 Laurence N. Charney가 2026년 8월 6일 자로 회사 주식에 대한 내부자 거래를 보고했습니다. 본 공시는 Form 4를 통한 지분 변동 사항의 공식적인 신고입니다.…more
$54.17+0.06%vs prev closeView filingShare
4 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 1d agoRegular26.10.23 23:58#●●●#●●●#●●●
TG Therapeutics Reports Positive Phase 1 Data for MS CAR-T Therapy
TG Therapeutics announced that 89% of evaluable patients in its Phase 1 trial for progressive multiple sclerosis showed stable or improved disability scores at day 90. This marks the first clinical evaluation of an allogeneic CD19-directed CAR T-cell therapy for this condition.…more
$54.17+0.06%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.12Pre-market26.10.12 20:31
●●●●●●●● ●●●●● ●●●●●●
TG Therapeutics announced that BRIUMVI demonstrated a significantly lower risk of MS disability progression compared to Ocrelizumab and Ofatumumab in indirect comparisons. This clinical data highlights the drug's competitive efficacy, potentially supporting its market position.…more
$54.17+0.06%vs prev closeShareBenzinga - 9.10Pre-market26.09.10 20:30
●●●●●●●● ●●●●● ●●●●●●
TG Therapeutics announced that its CEO will participate in the upcoming H.C. Wainwright Annual Global Investment Conference. This event is a standard investor relations activity and does not provide new material financial information.…more
$54.17+0.06%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report